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Abstract
The association of ovarian carcinoma risk with the polymorphism rs1271572 in the estrogen receptor beta (ESR2) gene was
examined in 4946 women with primary invasive ovarian carcinoma and 6582 controls in a pooled analysis of ten case-
control studies within the Ovarian Cancer Association Consortium (OCAC). All participants were non-Hispanic white women.
Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using unconditional logistic regression adjusted for site
and age. Women with the TT genotype were at increased risk of ovarian carcinoma compared to carriers of the G allele
(OR= 1.10; 95%; CI: 1.01–1.21; p = 0.04); the OR was 1.09 (CI: 0.99–1.20; p = 0.07) after excluding data from the center
(Hawaii) that nominated this SNP for OCAC genotyping A stronger association of rs1271572 TT versus GT/GG with risk was
observed among women aged #50 years versus older women (OR= 1.35; CI: 1.12–1.62; p = 0.002; p for interaction = 0.02)
that remained statistically significant after excluding Hawaii data (OR= 1.34; CI: 1.11–1.61; p = 0.009). No heterogeneity of
the association was observed by study, menopausal status, gravidity, parity, use of contraceptive or menopausal hormones,
tumor histological type, or stage at diagnosis. This pooled analysis suggests that rs1271572 might influence the risk of
ovarian cancer, in particular among younger women.
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Introduction
The mitogenic action of estrogen appears critical to the etiology
and progression of human gynecologic cancers [1]. The principal
biological activities of estrogens are to influence the growth,
differentiation, and function of reproductive tissues. Estrogens
interact with their receptors to mediate various signaling pathways
that are likely associated with the risk of ovarian cancer [2].
Estrogen receptors exist in two forms, estrogen receptor alpha
(ERa) and estrogen receptor beta (ERb) [3] which is the
predominant estrogen receptor in the ovary [4–6]. Although the
exact role of ERb in ovarian carcinogenesis remains to be
determined, recent in vivo and in vitro studies suggest that ERb is
involved with the control of cellular proliferation, motility and
apoptosis in ovarian cancer; and loss of ERb expression is
associated with tumor progression [7–10].
The human ERb gene (ESR2) is located on chromosome
14q23.2 spanning ,61.2 kb. Previously, the multiethnic Hawaiian
Ovarian Cancer Study evaluated four single nucleotide polymor-
phisms (SNPs) in the ESR2 gene, as well as their associated
haplotypes, in relation to risk of borderline and invasive ovarian
cancer and found that rs1271572 in the promoter region of the
gene may be an ovarian carcinoma susceptibility marker [11]. The
homozygous variant genotype (TT) carriers had a 79% increase in
risk (95% CI: 1.15–2.79) compared to women with the GG
genotype. White women had more than a two-fold increase in risk
(OR=2.42; 95% CI: 1.14–5.15). In the present study, we
performed a replication analysis of our putative significant findings
by genotyping rs1271572 among participants in nine additional
studies within the Ovarian Cancer Association Consortium
(OCAC), a forum for researchers to evaluate promising genetic
associations with ovarian cancer with increased power [12,13]. To
minimize the effects of population stratification, this study
included only white non-Hispanic women from developed
countries with comparable ovarian cancer incidence rates. Only
cases with invasive tumors were included.
Results
The mean age of cases (57.3 years; standard error = 0.2) and
controls (57.2 years; standard error = 0.1) was similar (Table 1).
Minor allele frequencies among controls ranged from 0.41 to 0.46
with no statistically significant differences in genotype distribution
among studies (p = 0.69) (Table S1) overall and by age group.
In all studies combined, women with the TT genotype had
increased ovarian carcinoma risk [odds ratio (OR) = 1.10; 95%
confidence interval (CI): 1.01–1.21; p= 0.04] compared to carriers
of any G allele (recessive genetic model) (Figure 1 and Table S2).
This OR was reduced to 1.09 (CI: 0.99–1.20; p= 0.07) after
excluding the Hawaii data. In addition to the HAW study, the
association was also statistically significant among AUS study
participants (OR=1.25; 95% CI: 1.01–1.54; p = 0.04) (Figure 1
and Table S2). Excluding the AUS study, where the genotype
deviated from Hardy-Weinberg equilibrium (HWE), slightly
attenuated the association of the rs1271572 SNP with ovarian
carcinoma risk (OR=1.07; 95% CI: 0.97–1.19; p= 0.09).
There was a significant interaction between genotype and age
(p = 0.02) (Figure 2 and Table S3). Among younger women (#50
years old), women with the TT genotype had a 35% increased risk
of ovarian carcinoma (95% CI: 1.2–1.67; p = 0.002) compared to
G allele carriers. No genetic associations were observed among
women .50 years old (OR=1.01; CI: 0.89–1.14; p= 0.91). The
association of the TT genotype with risk among women #50 years
old was also statistically significant in two individual studies, BAV
(OR=3.64; CI: 1.35–9.83; p = 0.01) and MAL (OR=2.05; CI:
1.07–3.91; p = 0.03) and in the pooled analysis when HAW data
were excluded (OR=1.34; 95% CI: 1.11–1.61; p= 0.009). The
association of the TT genotype with risk was also higher in
premenopausal (OR=1.20; CI: 0.99–1.45; p= 0.06) compared to
postmenopausal women (OR=1.10; CI: 0.98–1.24; p = 0.12),
although the test for heterogeneity in effect was not significant
(p = 0.82). No heterogeneity of the associations was observed
among studies for any of the models (p range: 0.13–0.84). No effect
modification by gravidity, parity, menopausal status, and use of
contraceptive and menopausal hormones was found for the
association of rs1271572 with risk (data not shown). No
heterogeneity of effects was observed by tumor histology (p range:
0.20–0.87) (Table S4) or stage at diagnosis (p = 0.87) (data not
shown).
Discussion
In this pooled analysis of ten case-control studies, we found a
modest association of the rs1271572 TT genotype with ovarian
carcinoma risk, particularly among younger women #50 years of
age. This significant association of rs1271572 with the risk of
ovarian cancer among younger women might result from the
higher concentrations of circulating estrogens among pre- and
ESR2 rs1271572 and Ovarian Carcinoma Risk
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perimenopausal women. By analogy, we hypothesize that among
postmenopausal women with lower estrogen levels, ESR2
functional variation would not be an important contributor to risk.
A potential causal association of rs1271572 with the risk of
ovarian cancer is supported by the finding that it maps to the
promoter of the ESR2 gene, near (253 bp upstream) the AP-4/
MyoD binding site [14], a region of predicted intense transcription
factor binding that might influence gene expression [7]. Tran-
scription factor AP-4 contains multiple dimerization domains that
function to promote ERb/ERb homodimer formation [15]. The
MyoD transcription regulator promotes the resistance of ER to
proteolytic degradation [16]. Therefore, the rs1271572 sequence
variation might reduce the anti-proliferative effects of ERb
proposed by altering ESR2 responsiveness to transcription
regulators.
Although the specific role of ERb in carcinogenesis is not
known, there is convincing evidence that ERb inhibits prolifera-
tion and motility of ovarian cancer cells and plays an important
Figure 1. Association of the ESR2 rs1271572 with invasive ovarian carcinoma risk. Forest plot of the ORs and 95% CIs for invasive ovarian
carcinoma risk associated with carriage of the ESR2 rs1271572 TT genotype versus GG/GT genotypes (recessive genetic model). P for heterogeneity of
the association of the ESR2 rs1271572 with risk by study = 0.60. Pooleda OR for all studies combined was 1.10 (95% CI: 1.01–1.21; p = 0.04). Pooledb OR
for all studies excluding HAW was 1.09 (95% CI: 0.99–1.20; p = 0.07).
doi:10.1371/journal.pone.0020703.g001
Table 1. Description of the studies included in the pooled analysis of the ESR2 rs1271572 and ovarian carcinoma risk.











1051 58.5 (0.3) 1148 56.7 (0.3)
BAV (Bavarian Ovarian Cancer Cases
and Controls)
Bavaria, Germany Hospital based 204 56.0 (0.7) 229 58.0 (0.7)
HAW (Hawaiian Ovarian Cancer Study) Hawaii, USA Population-based
case-control
64 55.0 (1.3) 152 56.8 (0.9)
MAL (The Danish Malignant Ovarian Tumor
Study)
Denmark 348 59.9 (0.6) 893 56.8 (0.4)
NCO (North Carolina Ovarian Cancer Study) North Carolina, USA Population-based
case-control
520 57.8 (0.5) 582 55.2 (0.4)




545 55.0 (0.5) 525 57.5 (0.5)
SEA (UK SEARCH Ovarian Cancer Study) United Kingdom 936 56.0 (0.3) 1198 55.0 (0.3)




265 51.4 (0.7) 338 48.2 (0.6)
UKO (UK Ovarian Cancer Population Study) United Kingdom 634 61.0 (0.4) 998 64.9 (0.3)
USC (Los Angeles County Case-Control
Studies of Ovarian Cancer)
California, USA Population-based
case-control
379 58.0 (0.5) 519 56.3 (0.5)
POOLED 4946 57.3 (0.2) 6582 57.2 (0.1)
doi:10.1371/journal.pone.0020703.t001
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role in apoptosis [8,17]. In a study by Lindgren et al.[9],
overexpressing ERb in an ovarian adenocarcinoma cancer cell line
PEO14 led to a 50% reduction in proliferative capacity. An
antitumor role of ERb in SK-OV-3 ovarian cancer cells that do
not express functional ERa has been reported by Treeck et al.
[18]. Down-regulation of ERb has also been noted in breast,
colon, and prostate cancers [19–21], malignancies that share some
etiologic features with ovarian cancer [22].
Previously, Pierce et al. evaluated [23] ESR2 variation in
relation to ovarian cancer risk, using a haplotype approach. No
statistically significant associations were found, although one
haplotype was associated with an increased risk of invasive clear
cell carcinoma. While the rs1271572 SNP was not genotyped in
this study, it was in the haplotype block represented by the
rs1271530 SNP which is in a strong linkage disequilibrium
(r2 = 0.9) with rs1271572 based on the HapMAP data among
whites. A previous genome-wide association study (GWAS) [24] of
ovarian cancer susceptibility, had limited power to detect modest
genetic associations: phase I included 1817 cases and 2353 and
had a 57% power to detect ORs as low as 1.10 under a log-
additive model and 23% under a recessive model. Sun et al. [25]
found an association of the rs1271572 polymorphism with the risk
of prostate cancer among Chinese men.
The strengths of this investigation are the population-based
nature of the studies included and the stringent genotyping
quality control procedures established by the OCAC. A further
Figure 2. Association of the ESR2 rs1271572 with invasive ovarian carcinoma risk in subgroups by age. Forest plot of the ORs and 95%
CIs for invasive ovarian carcinoma risk associated with carriage of the ESR2 rs1271572 TT genotype versus GG/GT genotypes (recessive genetic model)
in subgroups of women #50 (A) versus . 50 years (B) of age. Pooleda OR for all studies combined among women#50 years was 1.35 (95% CI: 1.12–
1.62; p = 0.002); p for heterogeneity among studies = 0.19. Pooledb OR for all studies excluding HAW was 1.34 (95% CI: 1.11–1.61; p = 0.009); p for
heterogeneity among studies = 0.29. P for interaction between ESR2 rs1271572 and age= 0.02.
doi:10.1371/journal.pone.0020703.g002
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strength is the large sample size and the relatively high allele
frequency. The False Positive Report Probability [26] for our
sample size and power was noteworthy (,0.5 level) for an OR of
1.10 for moderate to high prior probabilities ($0.10). Population
stratification might have influenced the results of our investiga-
tion. To minimize the population stratification effects, this study
included only white non-Hispanic women from developed
countries with comparable ovarian cancer incidence rates.
Nonetheless, false positive findings are possible and further
replication studies are being conducted to confirm the associa-
tion. Furthermore, our statistical power was limited to study
gene-environment interactions.
In conclusion, the results of this pooled analysis suggest that the
rs1271572 SNP in the ESR2 gene may influence the risk of
invasive ovarian carcinoma, especially among younger women.
Materials and Methods
Ethics Statement
All studies were approved by the review boards and ethics
committees of their parent institutions, and written informed
consent was obtained from all participants. In addition, Duke
University has Institutional Review Board approval as a data
coordinating center. All data were analyzed anonymously.
Study Design and Population
This pooled analysis of nine population-based studies from
Australia [the Australian Ovarian Cancer study and the
Australian Cancer Study: Ovarian Cancer (AUS)], the United
States [Genetic Epidemiology of Ovarian Cancer Study, Stanford
University, California (STA); Hawaiian Ovarian Cancer Study,
Honolulu, Hawaii (HAW); the North Carolina Ovarian Cancer
Study, North Carolina (NCO); the University of Southern
California Case-Control Studies of Ovarian Cancer, Los Angeles
County, California (USC)], and Europe [MALOVA Ovarian
Cancer Case-Control Study, Danish Cancer Society, Denmark
(MAL); Studies of Epidemiology and Risk Factors in Cancer
Heredity, United Kingdom (SEA); the United Kingdom Ovarian
Cancer Population Study (UKO); the Polish Ovarian Cancer
study, Poland (POC)] and one hospital-based study [Bavaria
Case-Control Study (BAV)] included 4946 cases with primary
histologically-confirmed invasive ovarian carcinoma and 6582
controls. Control subjects were randomly selected from the same
geographical areas as cases. Eligibility criteria for controls
included age 18 years or older, no prior history of ovarian
cancer, and having at least one intact ovary. All cases and
controls were non-Hispanic white women. A detailed description
of the studies has been previously published and is summarized in
Table 1 and Table S5. Epidemiological data were collected using
structured questionnaires that included socio-demographic and
health-related information, menstrual, reproductive, and gyneco-
logical histories. OCAC members submitted their epidemiolog-
ical data to Duke University where the variables have been
reviewed, cleaned, and merged. Histology and stage data were
available for 91% and 93% of cases, respectively. Information on
menopausal status was available for 91% of women. Data on
gravidity and parity was available for 86% (n= 9878 and
n= 9950, respectively) of women (it was missing for all POC
study participants and 5% of women from other studies
combined). Data on use of contraceptive hormones were
available for 83% (n= 9580) of women (the data were missing
for POC and BAV women and for 5% of women from all other
studies). Data on use of menopausal hormones were available
only for 30% (n = 1549) of postmenopausal women.
Genotyping
Genotyping for the AUS study was performed using the
Sequenom iPlex gold genotyping platform (Sequenom, Inc.). All
other studies used TaqMan allelic discrimination assay (TaqMan;
Applied Biosystems). We used the following quality control criteria
that were established by the OCAC to measure the acceptability of
the genotyping results: (1) .3% sample duplicates included, (2)
concordance rate for duplicate samples $98%, (3) overall call rate
(by study).95% and (4) call rate.90% for each 384-well plate (5)
no more than 5% difference in call rates between cases and
controls, and (6) cases and controls intermixed on each plate. In
addition, consistency across laboratories was confirmed by
genotyping a common set of 95 DNAs (90 CEPH trios and five
duplicate samples; HAPMAPPT01 provided by Coriell) with the
requirement of .98% concordance in genotype calls. All ten
studies met each of the criteria. Genotyping quality was also
assessed using tests for Hardy-Weinberg equilibrium (HWE). The
genotype distribution for the SNP among controls was consistent
with HWE in all but one study (AUS; p= 0.03). Exclusion of this
study did not appreciably affect the reported results.
Gene and allele nomenclature was according to the National
Center of Biotechnology Information.
Statistical analysis
Statistical analyses were performed using the SAS statistical
package (SAS release 9.2, SAS Institute Inc., Cary, NC). The chi-
square test for association was used to compare the allele
frequency distributions among controls across studies, and the
chi-square test for goodness-of-fit was used to test consistency with
the HWE for each study and overall. The association of the
rs1271572 polymorphism with ovarian carcinoma risk was
assessed using multivariate logistic regression models. ORs and
95% CIs were estimated separately for heterozygous and
homozygous variant T allele carriers, using women with the GG
genotype as the reference group. We also performed genetic
analyses testing a log-additive model in which genotype was
categorized by three levels (0, 1 and 2) representing number of
variant alleles. In addition, we compared risk among women with
the TT/GT versus GG genotypes (testing a dominant genetic
model) and among women with the TT genotype versus the GG/
GT genotypes (testing a recessive genetic model). Based on the
Akaike Information Criterion (AIC), the recessive model provided
the best fit for the data. All models are presented in tables for
comprehensiveness (supporting material).
Analyses were conducted for each study separately and for all
studies combined. All models were adjusted for age to control for a
potential residual confounding by imperfect matching. Heteroge-
neity of effects by study was examined using two different methods.
First, we included study site as a fixed effect covariate and
evaluated heterogeneity of the association of the rs1271572 SNP
with risk by study, using a Wald test of the genotype-study
interaction term. Second, we included study site as a random effect
using SAS GLIMMIX procedure. No heterogeneity was observed
in any of the models, and the results were the same. We also
conducted the analysis excluding data from the Hawaii study
which initially nominated the SNP for further validation. The
association of the rs1271572 with ovarian carcinoma risk by
histologic type (serous, mucinous, endometrioid, clear cell, mixed,
other specified epithelial, undifferentiated and other unknown
epithelial) was studied using polytomous logistic regression; the
estimated ORs among histological types were compared using the
Wald test. Heterogeneity of the association of the rs1271572
genotype with risk by age, gravidity, parity, menopausal status,
and use of contraceptive and menopausal hormones was evaluated
ESR2 rs1271572 and Ovarian Carcinoma Risk
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using the Wald test comparing group-specific parameters for the
rs1271572 genotype in the logistic regression models. All p-values
were based on two-tailed tests. We evaluated statistical significance
at the 5% level.
Supporting Information
Table S1 ESR2 rs1271572 genotype and minor allele frequen-
cies (MAF) among non-Hispanic white women by study.
(DOC)
Table S2 ESR2 rs1271572 genotype associations with ovarian
cancer risk by study.
(DOC)
Table S3 ESR2 rs1271572 genotype associations with ovarian
cancer risk by study stratified by age (#50 versus .50 years).
(DOC)
Table S4 Association of the ESR2 rs1271572 genotype with
ovarian carcinoma risk by histological type.
(DOC)
Table S5 Case ascertainment and selection of controls.
(DOC)
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